Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 82.83% |
| 2 | Healthcare | 3.13% |
| 3 | Technology | 2.97% |
| 4 | Financials | 2.19% |
| 5 | Consumer Discretionary | 2.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
12451
PUT
Riskified
RSKD
$1.03B
| $45.4K | ﹤0.01% |
9,600
-18,400
| -66% | -$85.3K |
2022 Q4
8 quarters
|
|
12452
CALL
Brookdale Senior Living
BKD
$2.6B
| $45.3K | ﹤0.01% |
9,000
-10,100
| -53% | -$57.8K |
2022 Q4
8 quarters
|
|
|
SLI
12453
CALL
Standard Lithium
SLI
$427M
| $45.3K | ﹤0.01% |
31,000
+12,600
| +68% | +$23.2K |
2021 Q3
13 quarters
|
|
12454
CALL
Fossil Group
FOSL
$418M
| $45.3K | ﹤0.01% |
27,100
+3,400
| +14% | +$4.97K |
2013 Q2
46 quarters
|
|
12455
Electromed
ELMD
$234M
| $45.2K | ﹤0.01% |
1,530
-17,432
| -92% | -$455K |
2024 Q1
3 quarters
|
|
|
ASA
12456
ASA Gold and Precious Metals
ASA
$1.05B
| $45.2K | ﹤0.01% |
+2,235
| New | +$46.6K |
2024 Q4
0 quarters
|
|
|
WOW
12457
CALL
DELISTED
WideOpenWest
WOW
| $45.1K | ﹤0.01% |
9,100
-5,400
| -37% | -$27.6K |
2023 Q1
7 quarters
|
|
12458
PUT
Enterprise Financial Services Corp
EFSC
$2.16B
| $45.1K | ﹤0.01% |
800
-200
| -20% | -$11.2K |
2022 Q4
8 quarters
|
|
12459
Femasys
FEMY
$17.4M
| $45.1K | ﹤0.01% |
+2,048
| New | +$46.6K |
2024 Q4
0 quarters
|
|
12460
PUT
Independent Bank
INDB
$3.76B
| $44.9K | ﹤0.01% |
700
| – | – |
2024 Q1
3 quarters
|
|
12461
Eldorado Gold
EGO
$10.1B
| $44.9K | ﹤0.01% |
3,019
-184,650
| -98% | -$3.05M |
2024 Q1
3 quarters
|
|
|
ADVM
12462
CALL
DELISTED
Adverum Biotechnologies
ADVM
| $44.8K | ﹤0.01% |
9,600
-13,600
| -59% | -$91.5K |
2024 Q2
2 quarters
|
|
|
DCBO
12463
PUT
Docebo
DCBO
$601M
| $44.8K | ﹤0.01% |
1,000
-22,700
| -96% | -$1.07M |
2022 Q4
8 quarters
|
|
|
ATYR
12464
aTyr Pharma
ATYR
$27.8M
| $44.7K | ﹤0.01% |
12,361
-954,246
| -99% | -$2.89M |
2022 Q4
8 quarters
|
|
12465
CALL
Ultralife
ULBI
$109M
| $44.7K | ﹤0.01% |
6,000
-400
| -6% | -$3.29K |
2023 Q3
5 quarters
|
|
|
NXLIW
12466
DELISTED
Nexalin Technology Inc Warrant
NXLIW
| $44.6K | ﹤0.01% |
121,275
-28,357
| -19% | -$10.3K |
2022 Q4
8 quarters
|
|
12467
CALL
Ambev
ABEV
$49.6B
| $44.6K | ﹤0.01% |
24,100
-12,000
| -33% | -$26.5K |
2020 Q3
17 quarters
|
|
12468
CALL
Abeona Therapeutics
ABEO
$286M
| $44.6K | ﹤0.01% |
8,000
-26,600
| -77% | -$164K |
2023 Q4
4 quarters
|
|
12469
PUT
Hudbay
HBM
$12B
| $44.5K | ﹤0.01% |
5,500
-19,100
| -78% | -$171K |
2020 Q4
16 quarters
|
|
12470
Research Solutions
RSSS
$68.9M
| $44.5K | ﹤0.01% |
10,735
-3,166
| -23% | -$10K |
2023 Q4
4 quarters
|
|
12471
CALL
Invesco Golden Dragon China ETF
PGJ
$83.5M
| $44.5K | ﹤0.01% |
1,700
-13,000
| -88% | -$352K |
2024 Q3
1 quarter
|
|
12472
CALL
Akebia Therapeutics
AKBA
$243M
| $44.5K | ﹤0.01% |
23,400
-104,100
| -82% | -$181K |
2020 Q1
19 quarters
|
|
12473
PUT
GrowGeneration
GRWG
$91.3M
| $44.4K | ﹤0.01% |
26,300
-12,000
| -31% | -$23K |
2020 Q3
17 quarters
|
|
12474
PUT
Paysign
PAYS
$811M
| $44.4K | ﹤0.01% |
14,700
+10,700
| +268% | +$37.5K |
2024 Q3
1 quarter
|
|
12475
Crown Crafts
CRWS
$26.6M
| $44.3K | ﹤0.01% |
+9,892
| New | +$45.7K |
2024 Q4
0 quarters
|
|
Similar funds
Citadel Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, Citadel Advisors held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Citadel Advisors's Q4 2024 filing shows 1,745 new, 6,427 increased, 6,082 reduced and 1,421 closed positions. Its largest new stake was Zoetis: 1,090,499 shares worth $178M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 83% a quarter earlier, followed by Healthcare and Technology.
- Citadel Advisors's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Citadel Advisors added most to Boeing in Q4 2024, an estimated $830M increase.
- Citadel Advisors's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Citadel Advisors fully exited Spotify in Q4 2024, selling an estimated $473M.
- Citadel Advisors's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Citadel Advisors opened 1,745 new positions and closed 1,421 in Q4 2024.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.